BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 29845629)

  • 1. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
    Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
    Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the optimal prolactin cutoff for predicting the presence of a pituitary adenoma in patients with polycystic ovary syndrome?
    Kim SI; Yoon JH; Park DC; Yang SH; Kim YI
    Int J Med Sci; 2023; 20(4):463-467. PubMed ID: 37057215
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.
    Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
    Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia.
    Sawers HA; Robb OJ; Walmsley D; Strachan FM; Shaw J; Bevan JS
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):321-6. PubMed ID: 9156042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Prolactin Level to Tumor Size Ratio as a Potential Parameter for Preoperative Differentiation of Prolactinomas from Hyperprolactinemia-Causing Non-functional Pituitary Adenomas.
    Kim JH; Hur KY; Hong SD; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
    World Neurosurg; 2022 Mar; 159():e488-e496. PubMed ID: 34958988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic ovary syndrome and prolactinoma association.
    Yavasoglu I; Kucuk M; Coskun A; Guney E; Kadikoylu G; Bolaman Z
    Intern Med; 2009; 48(8):611-3. PubMed ID: 19367058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin secretion in polycystic ovary syndrome (PCOS).
    Szosland K; Pawlowicz P; Lewiński A
    Neuro Endocrinol Lett; 2015; 36(1):53-8. PubMed ID: 25789595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycystic ovary syndrome or hyperprolactinaemia: a study of mild hyperprolactinaemia.
    Su HW; Chen CM; Chou SY; Liang SJ; Hsu CS; Hsu MI
    Gynecol Endocrinol; 2011 Jan; 27(1):55-62. PubMed ID: 20504100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor volume improves preoperative differentiation of prolactinomas and nonfunctioning pituitary adenomas.
    Wright K; Lee M; Escobar N; Pacione D; Young M; Fatterpekar G; Agrawal N
    Endocrine; 2021 Oct; 74(1):138-145. PubMed ID: 33966173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging.
    Kawaguchi T; Ogawa Y; Tominaga T
    BMC Res Notes; 2014 Aug; 7():555. PubMed ID: 25142896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The detection of macroprolactin by precipitation and ultrafiltration methods.
    Beda-Maluga K; Pisarek H; Komorowski J; Pawlikowski M; Świętosławski J; Winczyk K
    Endokrynol Pol; 2011; 62(6):529-36. PubMed ID: 22144220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. To what extent does polycystic ovary syndrome influence the cut-off value of prolactin? Findings of a community-based study.
    Mahboobifard F; Rahmati M; Amiri M; Azizi F; Ramezani Tehrani F
    Adv Med Sci; 2022 Mar; 67(1):79-86. PubMed ID: 34998115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycystic ovary syndrome and hyperprolactinemia are distinct entities.
    Filho RB; Domingues L; Naves L; Ferraz E; Alves A; Casulari LA
    Gynecol Endocrinol; 2007 May; 23(5):267-72. PubMed ID: 17558684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome.
    Hernández I; Parra A; Méndez I; Cabrera V; Cravioto MC; Mercado M; Díaz-Sánchez V; Larrea F
    Arch Med Res; 2000; 31(2):216-22. PubMed ID: 10880731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery.
    Scanlon MF; Peters JR; Salvador J; Richards SH; John R; Howell S; Williams ED; Thomas JP; Hall R
    Clin Endocrinol (Oxf); 1986 Apr; 24(4):435-46. PubMed ID: 3091297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of endocrine tests. A: the TRH test in patients with hyperprolactinaemia.
    Le Moli R; Endert E; Fliers E; Prummel MF; Wiersinga WM
    Neth J Med; 2003 Feb; 61(2):44-8. PubMed ID: 12735420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin Level in Polycystic Ovary Syndrome (PCOS): An approach to the diagnosis and management.
    Davoudi Z; Araghi F; Vahedi M; Mokhtari N; Gheisari M
    Acta Biomed; 2021 Nov; 92(5):e2021291. PubMed ID: 34738596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The value of functional tests in diagnosis of prolactinoma].
    Klockenbusch W; Distler W; von Ditfurth M; Graf M; Jahn K
    Geburtshilfe Frauenheilkd; 1990 May; 50(5):383-7. PubMed ID: 2115483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprolactinemia and prolactinoma.
    Romijn JA
    Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia.
    Vilar L; Naves LA; Freitas MC; Lima M; Canadas V; Albuquerque JL; Lyra R; Azevedo MF; Casulari LA
    Minerva Endocrinol; 2007 Jun; 32(2):79-86. PubMed ID: 17557033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.